BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.44 USD | +1.95% |
|
+1.79% | -22.15% |
Evolution of the Average Target: Biogen Inc.
Evolution of the Target Price: Biogen Inc.
Changes in Analyst Recommendations: Biogen Inc.
80e2d348.ZxdEROoJ4yU7E0ALwbIARrnp3iI_Jjg1XbLMGkJHYZA.DFYAI5pxmXptYi1klOcxMtfbvFQHE3Z7COWPVi9-IPESdD40qEXbRxZScA~29a1217ee4f88cb9057f8f7f767d6fd1
More recommendations
| Analyst Opinion | 4m Revision of opinion | Divergence of analysts' opinions | Divergence of Target Price | Ecart obj. / dr | ||
|---|---|---|---|---|---|---|
| +37.37% | ||||||
| +5.35% | ||||||
| +7.68% | ||||||
| +2.95% | ||||||
| +47.23% | ||||||
| -14.97% | ||||||
| +13.74% | ||||||
| -8.61% | ||||||
| -0.83% | ||||||
| +32.94% | ||||||
| Average | +12.28% | |||||
| Weighted average by Cap. | +10.24% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
201.44USD
Average target price
271.42USD
Spread / Average Target
+34.74%
High Price Target
342.00USD
Spread / Highest target
+69.78%
Low Price Target
190.00USD
Spread / Lowest Target
-5.68%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Wedbush | |
| Argus | |
| Redburn Atlantic | |
| HSBC | |
| Guggenheim | |
| HC Wainwright | |
| Barclays | |
| Canaccord Genuity | |
| Goldman Sachs | |
| Morgan Stanley | |
| Piper Sandler | |
| RBC Capital Markets | |
| Needham & Co. | |
| BMO Capital | |
| Oppenheimer | |
| UBS | |
| JPMorgan Chase | |
| Stifel Nicolaus | |
| TD Cowen | |
| Scotiabank | |
| Baird | |
| Wells Fargo Securities | |
| BofA Securities | |
| Raymond James | |
| Mizuho Securities | |
| Atlantic Equities | |
| Jefferies & Co. | |
| Truist Securities | |
| Cowen | |
| SVB Securities LLC | |
| SVB Leerink | |
| Cantor Fitzgerald | |
| Bernstein | |
| William Blair & Co. | |
| Citigroup | |
| Credit Suisse | |
| DZ Bank |
Trading Rating
Investor Rating
ESG Refinitiv
B-
- Stock Market
- Equities
- BIIB Stock
- Consensus Biogen Inc.
